Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy Versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy, with or without chemotherapy, with chemotherapy alone in treating patients with stage I or stage IIA Hodgkin's disease.


Options:
A: Arm Label: Favorable - Standard - any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Standard - Any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Intervention Type: DRUG; Name: ABVD q4 weeks; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Standard - Any PET outcome | Intervention Type: DRUG; Name: BEACOPP escalated q3 weeks; Assigned to Arm(s): Favorable - Experimental - PET positive, Unfavorable - Experimental - PET positive | Intervention Type: RADIATION; Name: IN-RT 30 Gy (+ boost 6 Gy residual); Assigned to Arm(s): Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome | Intervention Type: PROCEDURE; Name: FDG-PET scan; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome
B: Arm Label: Arm I (Patients off-therapy before callback-Induction only); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm II (RER with CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm III (RER with CR [ABVE-PC]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm IV (RER with less than CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm V (RER with PD); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VI (SER [DECA, ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Cytarabine, Drug: Dexamethasone, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VII (SER [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Intervention Type: BIOLOGICAL; Name: Bleomycin Sulfate; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: RADIATION; Name: Involved-Field Radiation Therapy; Assigned to Arm(s): Arm II (RER with CR [ABVE-PC, IFRT]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Vincristine Sulfate Liposome; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT])
C: Arm Label: Radiotherapy or ABVD + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine, Radiation: radiation therapy | Arm Label: ABVD Alone; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: vinblastine; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Radiotherapy or ABVD + Radiotherapy
D: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Involved Field Radiotherapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Other: No further treatment | Intervention Type: RADIATION; Name: Involved Field Radiotherapy; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: No further treatment; Assigned to Arm(s): Arm II

Answer: C